1111637-73-0

Basic information

• Product Name: 3-PyridineMethanol, 5-broMo-2-fluoro-α-Methyl-
• Synonyms: 3-PyridineMethanol, 5-broMo-2-fluoro-α-Methyl-;1-(5-Bromo-2-fluoro-pyridin-3-yl)-ethanol
• CAS NO: 1111637-73-0
• Molecular Formula: C7H7BrFNO
• Molecular Weight: 220.05
• Mol File: 1111637-73-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 288.881 °C at 760 mmHg
• Flash Point: 128.511 °C
• Appearance: /
• Density: 1.641 g/cm³
• CAS DataBase Reference: 3-PyridineMethanol, 5-broMo-2-fluoro-α-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PyridineMethanol, 5-broMo-2-fluoro-α-Methyl-(1111637-73-0)
• EPA Substance Registry System: 3-PyridineMethanol, 5-broMo-2-fluoro-α-Methyl-(1111637-73-0)

Safety Data

• Hazardous Substances Data: 1111637-73-0(Hazardous Substances Data)

Usage

General Description

3-PyridineMethanol, 5-broMo-2-fluoro-α-Methyl- is a chemical compound with the molecular formula C8H8BrFNOS. It is a derivative of pyridine and contains a bromine and a fluorine atom, along with a methyl group. This chemical is commonly used in pharmaceutical research and development, and may have potential applications in medicinal and pharmaceutical chemistry. 3-PyridineMethanol, 5-broMo-2-fluoro-α-Methyl- may have potential therapeutic properties and is an important building block in the synthesis of various bioactive compounds. It is important to handle and use this chemical with care, following proper safety protocols and procedures.

Upstream product

• 875781-15-0 5-bromo-2-fluoro-3-pyridinecarboxaldehyde 
• 766-11-0 5-bromo-2-fluoropyridine 
• 75-07-0 acetaldehyde 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 1111637-74-1 1-(5-bromo-2-fluoropyridin-3-yl)ethanone 
• 916258-24-7 tert-butyl 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 

Relevant articles and documents

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer

A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast

LPA RECEPTOR ANTAGONISTS AND USES THEREOF

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).

FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.